BillionToOneBLLN +2.04%13 Return-on-Tangible-Asset is 10.79% as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, BillionToOne ranks better than 72.9% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BillionToOne's annualizedNet Income for the quarter that ended in Mar. 2026 was $71.9 Mil. BillionToOne's average total tangible assets for the quarter that ended in Mar. 2026 was $666.4 Mil. Therefore, BillionToOne's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 10.79%.
The historical rank and industry rank for BillionToOne's Return-on-Tangible-Asset or its related term are showing as below:
BLLN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -43.16 Med: -16.85 Max: 5.96
Current: 5.96
During the past 3 years, BillionToOne's highest Return-on-Tangible-Asset was 5.96%. The lowest was -43.16%. And the median was -16.85%.
BLLN's Return-on-Tangible-Asset is ranked better than 72.9% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.325
vs BLLN: 5.96
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BillionToOne Return-on-Tangible-Asset Related Terms
BillionToOne Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BillionToOne's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLLN vs SHC, VCYT, RDNT: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, BillionToOne's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BillionToOne's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 10.79% mean?
BillionToOne (BLLN) has a Return-on-Tangible-Asset of 10.79% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #58 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 27.1%.
Is BillionToOne's Return-on-Tangible-Asset too high?
BillionToOne's current Return-on-Tangible-Asset is 10.79%. Based on the distribution chart, BillionToOne ranks #58 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Return-on-Tangible-Asset compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #58 out of 214 companies for Return-on-Tangible-Asset. This puts BillionToOne in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BillionToOne and its competitors. BillionToOne's current Return-on-Tangible-Asset is 10.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Return-on-Tangible-Asset of 10.79%. The current Return-on-Tangible-Asset is 10.79%. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BillionToOne (BLLN), the current Return-on-Tangible-Asset is 10.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 